SLGN Stock Analysis: Silgan Holdings | NYSE
Packaging & Containers | NYSE, USA | Market Cap: 3.721m USD | 12M Return: -15.4% | US8270481091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 46.2M
EPS Trend: 64.0%
Qual. Beats: 0
Rev. Trend: 80.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Silgan Holdings Inc. is a U.S.-based manufacturer of rigid packaging solutions serving consumer goods end-markets across North America and international markets. The company operates through three business segments: Dispensing and Specialty Closures, Metal Containers, and Custom Containers, offering products such as dispensing pumps, specialty caps, steel and aluminum cans, and custom PET and polyethylene containers. Its products are used by brand owners in fragrance and beauty, food and beverage, personal and health care, home care, and lawn and garden applications, with customers ranging from food processors to makers of condiments, pet food, and powdered drink mixes. Silgan distributes primarily through its direct sales force, supplemented by distributor networks and an online catalog, and has been headquartered in Norwalk, Connecticut since its founding in 1987.
As a constituent of the Materials sector within the Metal, Glass & Plastic Containers sub-industry, Silgan participates in a defensive packaging segment whose revenue tends to track closely with underlying consumer staples volume rather than discretionary spending. The rigid packaging business model is typically characterized by long-standing customer relationships with branded consumer goods companies and multi-year supply agreements, which contribute to relatively stable, recurring order patterns.
- Metal Containers demand tied to pet food volume growth
- Dispensing Closures margins expand on product mix shift
- Custom Containers faces resin cost volatility pressure
| Net Income: 270.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.93 > 1.0 |
| NWC/Revenue: 10.54% < 20% (prev 24.44%; Δ -13.91% < -1%) |
| CFO/TA 0.07 > 3% & CFO 640.8m > Net Income 270.3m |
| Net Debt (4.68b) to EBITDA (911.8m): 5.13 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.8m) vs 12m ago -1.40% < -2% |
| Gross Margin: 17.07% > 18% (prev 17.04%; Δ 0.03% > 0.5%) |
| Asset Turnover: 70.30% > 50% (prev 70.47%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: 3.09 > 6 (EBIT TTM 579.3m / Interest Expense TTM 187.2m) |
| A: 0.07 (Total Current Assets 3.29b - Total Current Liabilities 2.59b) / Total Assets 9.60b |
| B: 0.39 (Retained Earnings 3.70b / Total Assets 9.60b) |
| C: 0.06 (EBIT TTM 579.3m / Avg Total Assets 9.51b) |
| D: 0.33 (Book Value of Equity 2.38b / Total Liabilities 7.22b) |
| Altman-Z'' = 2.49 = A |
| DSRI: 1.16 (Receivables 1.45b/1.24b, Revenue 6.68b/6.63b) |
| GMI: 1.00 (GM 17.04% / 17.07%) |
| AQI: 0.92 (AQ_t 0.41 / AQ_t-1 0.45) |
| SGI: 1.01 (Revenue 6.68b / 6.63b) |
| TATA: -0.04 (NI 270.3m - CFO 640.8m) / TA 9.60b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 35.44 with a total of 868,450 shares traded. Over the past week, the price has changed by +1.63%, over one month by -7.59%, over three months by -19.06% and over the past year by -15.36%.
Current recommended Stop Loss: 34.10 (which is 3.8% or 1.2 ATR below the current price).
Silgan Holdings has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy SLGN.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.9 | 51.9% |
P/E Trailing = 13.8078
P/E Forward = 8.8417
P/S = 0.5569
P/B = 1.6501
P/EG = 0.8384
Revenue TTM = 6.68b USD
EBIT TTM = 579.3m USD
EBITDA TTM = 911.8m USD
Long Term Debt = 3.66b USD (from longTermDebt, last quarter)
Short Term Debt = 1.18b USD (from shortTermDebt, last quarter)
Debt = 5.03b USD (from shortLongTermDebtTotal, last quarter) + Leases 195.7m
Net Debt = 4.68b USD (calculated: Debt 5.03b - CCE 351.5m)
Enterprise Value = 8.40b USD (3.72b + Debt 5.03b - CCE 351.5m)
Interest Coverage Ratio = 3.09 (Ebit TTM 579.3m / Interest Expense TTM 187.2m)
EV/FCF = 24.50x (Enterprise Value 8.40b / FCF TTM 342.8m)
FCF Yield = 4.08% (FCF TTM 342.8m / Enterprise Value 8.40b)
FCF Margin = 5.13% (FCF TTM 342.8m / Revenue TTM 6.68b)
Net Margin = 4.05% (Net Income TTM 270.3m / Revenue TTM 6.68b)
Gross Margin = 17.07% ((Revenue TTM 6.68b - Cost of Revenue TTM 5.54b) / Revenue TTM)
Gross Margin QoQ = 17.95% (prev 17.02%)
Tobins Q-Ratio = 0.87 (Enterprise Value 8.40b / Total Assets 9.60b)
Interest Expense / Debt = 3.72% (Interest Expense 187.2m / Debt 5.03b)
Taxrate = 31.49% (123.5m / 392.1m)
NOPAT = 396.9m (EBIT 579.3m * (1 - 31.49%))
Current Ratio = 1.27 (Total Current Assets 3.29b / Total Current Liabilities 2.59b)
Debt / Equity = 2.11 (Debt 5.03b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 5.13 (Net Debt 4.68b / EBITDA 911.8m)
Debt / FCF = 13.65 (Net Debt 4.68b / FCF TTM 342.8m)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.84% (Net Income 270.3m / Total Assets 9.60b)
RoE = 11.69% (Net Income TTM 270.3m / Total Stockholder Equity 2.31b)
RoCE = 9.71% (EBIT 579.3m / Capital Employed (Equity 2.31b + L.T.Debt 3.66b))
RoIC = 5.05% (NOPAT 396.9m / Invested Capital 7.85b)
WACC = 4.48% (E(3.72b)/V(8.75b) * Re(7.10%) + D(5.03b)/V(8.75b) * Rd(3.72%) * (1-Tc(0.31)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.98 | Cagr: -0.52%
[DCF] Terminal Value 73.10% ; FCFF base≈450.4m ; Y1≈395.0m ; Y5≈319.1m
[DCF] Fair Price = 4.21 (EV 5.12b - Net Debt 4.68b = Equity 444.6m / Shares 105.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 63.97 | EPS CAGR: 4.03% | SUE: 0.83 | # QB: 0
Revenue Correlation: 79.99 | Revenue CAGR: 7.08% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.25 | Chg30d=-0.34% | Revisions=-46% | Analysts=12
EPS current Year (2026-12-31): EPS=3.82 | Chg30d=-0.13% | Revisions=+46% | GrowthEPS=+2.6% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=4.09 | Chg30d=-0.10% | Revisions=-25% | GrowthEPS=+7.2% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: -9% (up=13, down=16)